200 related articles for article (PubMed ID: 34563945)
1. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia.
Carraway HE; Sawalha Y; Gojo I; Lee MJ; Lee S; Tomita Y; Yuno A; Greer J; Smith BD; Pratz KW; Levis MJ; Gore SD; Ghosh N; Dezern A; Blackford AL; Baer MR; Gore L; Piekarz R; Trepel JB; Karp JE
Leuk Res; 2021 Nov; 110():106707. PubMed ID: 34563945
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol.
Bassan R; Fumagalli M; Chiaretti S; Audisio E; Cascavilla N; Paolini S; Delia M; Cerqui E; Micò C; Fabbiano F; Canichella M; Scattolin AM; Perfetti P; Paoloni F; Iodice M; Vitale A; Della Starza I; Fazi P; Vignetti M; Foà R
Leuk Lymphoma; 2019 Dec; 60(14):3482-3492. PubMed ID: 31298059
[TBL] [Abstract][Full Text] [Related]
3. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group.
Saito T; Hatta Y; Hayakawa F; Takahashi T; Hagihara M; Iida H; Minauchi K; Yamazaki E; Sugiura I; Murayama T; Sakura T; Mori N; Imai K; Yahagi Y; Atsuta Y; Saito AM; Hirakawa A; Kiyoi H; Matsumura I; Miyazaki Y;
Int J Hematol; 2021 Mar; 113(3):395-403. PubMed ID: 33230647
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
5. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.
Faderl S; Balakrishnan K; Thomas DA; Ravandi F; Borthakur G; Burger J; Ferrajoli A; Cortes J; O'Brien S; Kadia T; Feliu J; Plunkett W; Gandhi V; Kantarjian HM
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):231-8. PubMed ID: 24440659
[TBL] [Abstract][Full Text] [Related]
6. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
[TBL] [Abstract][Full Text] [Related]
7. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
Cooper TM; Razzouk BI; Gerbing R; Alonzo TA; Adlard K; Raetz E; Gamis AS; Perentesis J; Whitlock JA
Pediatr Blood Cancer; 2013 Jul; 60(7):1141-7. PubMed ID: 23335239
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
Pili R; Salumbides B; Zhao M; Altiok S; Qian D; Zwiebel J; Carducci MA; Rudek MA
Br J Cancer; 2012 Jan; 106(1):77-84. PubMed ID: 22134508
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea.
Choi JY; Hong CR; Hong KT; Kang HJ; Kim S; Lee JW; Jang PS; Chung NG; Cho B; Kim H; Koh KN; Im HJ; Seo JJ; Hahn SM; Han JW; Lyu CJ; Yang EJ; Lim YT; Yoo KH; Koo HH; Kook H; Jeon IS; Cho H; Shin HY
Cancer Res Treat; 2021 Oct; 53(4):1184-1194. PubMed ID: 33421973
[TBL] [Abstract][Full Text] [Related]
11. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
[TBL] [Abstract][Full Text] [Related]
12. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Steinherz PG; Shukla N; Kobos R; Steinherz L
Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
[TBL] [Abstract][Full Text] [Related]
14. Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup.
Huguet F; Leguay T; Raffoux E; Rousselot P; Vey N; Pigneux A; Ifrah N; Dombret H
Leuk Lymphoma; 2015 Apr; 56(4):847-57. PubMed ID: 24996442
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.
Shukla N; Kobos R; Renaud T; Steinherz LJ; Steinherz PG
Pediatr Blood Cancer; 2014 Mar; 61(3):431-5. PubMed ID: 24115731
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia.
Farag SS; Wood LL; Schwartz JE; Srivastava S; Nelson RP; Robertson MJ; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Jones DR
Leukemia; 2011 Apr; 25(4):599-605. PubMed ID: 21252987
[TBL] [Abstract][Full Text] [Related]
17. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
Zeidan AM; Ricklis RM; Carraway HE; Yun HD; Greer JM; Smith BD; Levis MJ; McDevitt MA; Pratz KW; Showel MM; Gladstone DE; Gore SD; Karp JE
Br J Haematol; 2012 Jul; 158(2):198-207. PubMed ID: 22594769
[TBL] [Abstract][Full Text] [Related]
19. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
[TBL] [Abstract][Full Text] [Related]
20. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.
Salzer WL; Burke MJ; Devidas M; Chen S; Gore L; Larsen EC; Borowitz M; Wood B; Heerema NA; Carroll AJ; Hilden JM; Loh ML; Raetz EA; Winick NJ; Carroll WL; Hunger SP
Cancer; 2018 Mar; 124(6):1150-1159. PubMed ID: 29266189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
